Antdorf, Germany

Christina Porzig

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Roche Diagnostics Operations, Inc.. Active years: 2022.


% Patents Active = 100.0

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Christina Porzig: Innovator in Cardiac Diagnostics

Introduction

Christina Porzig is a notable inventor based in Antdorf, Germany. She has made significant contributions to the field of cardiac diagnostics through her innovative research and development of antibodies.

Latest Patents

Christina holds a patent for "Antibodies recognizing genetic variants of NT-proBNP." This patent describes an antibody that specifically binds to a mutated NT-proBNP, which includes mutations substituting arginine at position 46 with histidine and substituting glutamic acid at position 43 with aspartic acid. The patent also encompasses a mutated NT-proBNP or fragment thereof, as well as kits containing the antibody or the mutated NT-proBNP. Furthermore, the disclosure includes a method for diagnosing heart failure.

Career Highlights

Christina Porzig is currently employed at Roche Diagnostics Operations, Inc., where she continues to advance her research in the field of diagnostics. Her work has been instrumental in developing tools that aid in the early detection of heart conditions.

Collaborations

Throughout her career, Christina has collaborated with esteemed colleagues such as Klaus Hallermayer and Monika Soukupova. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Christina Porzig's contributions to cardiac diagnostics through her patented innovations highlight her role as a leading inventor in the medical field. Her work not only advances scientific knowledge but also has the potential to improve patient care and outcomes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…